SCHEMBL2091283

SCHEMBL2091283

CN1CCN(CCCC(N)=O)CC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.52
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.45
CYP1A2 P05177 1/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
RAD52 P43351 1/20 0.43
HTR7 P34969 2/20 0.43
RAB9A P51151 1/20 0.40
TP53 P04637 1/20 0.39
SIGMAR1 Q99720 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7427001 0.98 PAOX (0.58) PAOXL3MBTL1TSHRSMN1; SMN2CYP1A2
SCHEMBL28996572 0.92 L3MBTL1 (0.55) PAOXL3MBTL1TSHRSMN1; SMN2CYP1A2
SCHEMBL30479937 0.92 PAOX (0.72) PAOXL3MBTL1TSHRALDH1A1HTR7
SCHEMBL2852219 0.89 L3MBTL1 (0.65) PAOXL3MBTL1TSHRSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL7430675 0.87 L3MBTL1 (0.63) PAOXL3MBTL1TSHRSMN1; SMN2ALDH1A1
SCHEMBL5799141 0.87 L3MBTL1 (0.53) PAOXL3MBTL1TSHRSMN1; SMN2LMNA
SCHEMBL29973082 0.85 L3MBTL1 (0.50) PAOXL3MBTL1TSHRSMN1; SMN2CYP1A2
Hydrochloric Acid SCHEMBL8742882 0.83 L3MBTL1 (0.48) PAOXL3MBTL1TSHRSMN1; SMN2CYP1A2
SCHEMBL11523231 0.83 PAOX (0.85) PAOXTSHRSMN1; SMN2CYP1A2MAPK1
SCHEMBL6956288 0.83 PAOX (0.60) PAOXTSHRSMN1; SMN2CYP1A2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368650-A1 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS CHIESI FARMACEUTICI S.P.A. (IT) 2025-12-04 US claimed
CN-118201915-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2024-06-14 CN claimed
EP-3353168-A1 COMPOUNDS AND METHODS FOR INHIBITING JAK Dizal (Jiangsu) Pharmaceutical Co., Limited (CN) 2018-08-01 EP claimed
WO-2017050938-A1 COMPOUNDS AND METHODS FOR INHIBITING JAK ASTRAZENECA AB (SE) 2017-03-30 WO claimed
EP-1401451-A2 QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2004-03-31 EP claimed
WO-2002102782-A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE NOVARTIS AG (CH) 2002-12-27 WO claimed
WO-2000014109-A1 BASIC PRODUCTS HAVING ANTAGONISTIC ACTIVITY ON THE NK-1 RECEPTOR AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS MENARINI RICERCHE S.P.A. (IT) 2000-03-16 WO claimed
EP-0375451-A2 Compounds having a renin-inhibiting activity BEECHAM GROUP PLC (GB) 1990-06-27 EP claimed
US-20250368650-A1 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS CHIESI FARMACEUTICI S.P.A. (IT) 2025-12-04 US disclosed
US-20250269050-A1 CYCLIC DICHALCOGENIDE ADC LINKER UNITS AND USES THEREOF THORN SESHOLD OLIVER (DE) 2025-08-28 US disclosed
CN-118201915-A Pyridazinylamino derivatives as ALK5 inhibitors 奇斯药制品公司 2024-06-14 CN disclosed
CN-115427032-A Pharmaceutical composition and use thereof 浙江养生堂天然药物研究所有限公司 2022-12-02 CN disclosed
WO-2020232056-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-11-19 WO disclosed
EP-2507232-B1 PROLINE DERIVATIVES NATIONAL HEALTH RES INST (TW) 2019-03-20 EP disclosed
US-20090281072-A1 Diaminopyrimidinecarboxamide Derivative ASTELLAS PHARM INC. (JP) 2009-11-12 US disclosed
US-7449456-B2 Diaminopyrimidinecarboxamide derivative ASTELLAS PHARMA, INC. (JP) 2008-11-11 US disclosed
EP-1401451-A2 QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2004-03-31 EP disclosed
WO-2002102782-A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE NOVARTIS AG (CH) 2002-12-27 WO disclosed
WO-2000014109-A1 BASIC PRODUCTS HAVING ANTAGONISTIC ACTIVITY ON THE NK-1 RECEPTOR AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS MENARINI RICERCHE S.P.A. (IT) 2000-03-16 WO disclosed
EP-0375451-A2 Compounds having a renin-inhibiting activity BEECHAM GROUP PLC (GB) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368650-A1 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS ALK, TGFBR2, TGFBR1 PAOX 1528/4885L3MBTL1 4590/4885TSHR 649/4885
US-20250269050-A1 CYCLIC DICHALCOGENIDE ADC LINKER UNITS AND USES THEREOF CCL2, UACA, CAD PAOX 3513/4885L3MBTL1 2632/4885TSHR 1876/4885
US-20090281072-A1 Diaminopyrimidinecarboxamide Derivative STAT6, STAT4, STAT3 PAOX 1930/4885L3MBTL1 1229/4885TSHR 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.